Patents
Literature
5 results about "Death domain" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The death domain (DD) is a protein interaction module composed of a bundle of six alpha-helices. DD is a subclass of protein motif known as the death fold and is related in sequence and structure to the death effector domain (DED) and the caspase recruitment domain (CARD), which work in similar pathways and show similar interaction properties. DD bind each other forming oligomers. Mammals have numerous and diverse DD-containing proteins. Within these proteins, the DD domains can be found in combination with other domains, including: CARDs, DEDs, ankyrin repeats, caspase-like folds, kinase domains, leucine zippers, leucine-rich repeats (LRR), TIR domains, and ZU5 domains.
Use of compounds for the manufacture of a malt1 inhibitor medicament
The application provides application of a compound of a general formula I or a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug, a tautomer, a stereoisomer thereof as a MALT1 inhibitor, the MALT1 tumor inhibitor can inhibit the expression of a MALT1 gene or inactivate the function of a MALT1 protein, the compound of the general formula can play the role of inhibiting the expression of the MALT1 gene or inactivating the function of the MALT1 protein by affecting the expression of a MALT1 protein death domain. The screened small molecule compound can inhibit the RNA expression of a marker in tumor cells and delay tumor progression in a tumor model mouse; in addition, when the small molecule compound is combined with an immune checkpoint inhibitor, the small molecule compound can synergize with the immune checkpoint inhibitor, and the curative effect is significantly enhanced.
Owner:XZYP (BEIJING) BIOTECH CO LTD
Oncolytic viruses for delivery of therapeutic polypeptides
Provided are oncolytic viruses that encode a death domain (DD) polypeptide fragment of human CD95 or a serine protease, and related compositions and methods for treating cancers.
Owner:ONCHILLES PHARMA INC
Use of compound in preparation of malt1 inhibitor drug
PCT designated stageWO2026114442A2Heterocyclic compound active ingredientsEfficacyPharmaceutical medicine
Provided in the present invention is the use of a compound of general formula I or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof acting as an MALT1 inhibitor. The MALT1 tumor inhibitor can inhibit the expression of an MALT1 gene or inactivate the function of an MALT1 protein. The compound of the general formula achieves the effect of inhibiting the expression of the MALT1 gene or inactivating the function of the MALT1 protein by means of affecting the expression of an MALT1 protein death domain. The screened small molecule compound is capable of inhibiting the RNA expression of a marker in tumor cells and delaying tumor progression in tumor model mice. In addition, the use of the compound in combination with an immune checkpoint inhibitor can produce a synergistic effect and significantly enhance the efficacy.
Owner:XZYP (BEIJING) BIOTECH CO LTD
MALT1 tumor inhibitor, medicine containing MALT1 tumor inhibitor and application of MALT1 tumor inhibitor
The invention provides an MALT1 tumor inhibitor, the MALT1 tumor inhibitor can inhibit expression of MALT1 genes or inactivate functions of MALT1 proteins, and the MALT1 tumor inhibitor is selected from a preparation capable of influencing expression of a death structural domain of the MALT1 proteins, a preparation capable of knocking out the death structural domain, a preparation capable of changing the structure of the death structural domain or a preparation capable of degrading the death structural domain. The MALT1 tumor inhibitor can effectively treat various solid tumors and can treat tumors which cannot be treated by an immune checkpoint inhibitor, in addition, when the MALT1 tumor inhibitor is combined with the immune checkpoint inhibitor, the MALT1 tumor inhibitor can achieve a synergistic effect, and the curative effect is remarkably enhanced.
Owner:XZYP (BEIJING) BIOTECH CO LTD
Treatment of repeat expansion disease
Provided herein is technology relating to treatment of diseases caused by hexanucleotide repeat expansion in the C9orf72 gene and particularly, but not exclusively, to methods of treating disease by decreasing the activity of death domain-associated protein (DAXX) and / or normalizing histone modifications and chromatin structure.
Owner:JOHNS HOPKINS UNIVERSITY